NICE TA704 - Trastuzumab deruxtecan for treating
HER2-positive unresectable or metastatic breast cancer after 2 or more
anti-HER2 therapies
NICE TA862 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (Decision date - March 2023)
DNP:
NICE TA879 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (Terminated appraisal) (Decision date - May 2023)
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
